MDMA — Pharmala Biotech Holdings Income Statement
0.000.00%
Last trade - 00:00- CA$14.98m
- CA$14.79m
- CA$1.04m
Annual income statement for Pharmala Biotech Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | 2024 August 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0.078 | 0.532 | 1.04 |
| Cost of Revenue | ||||
| Gross Profit | — | 0.076 | 0.454 | 0.887 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 2.51 | 1.06 | 1.31 | 1.86 |
| Operating Profit | -2.51 | -0.986 | -0.78 | -0.824 |
| Net Income Before Taxes | -2.51 | -0.986 | -0.78 | -0.824 |
| Net Income After Taxes | -2.51 | -0.986 | -0.78 | -0.824 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -2.51 | -0.986 | -0.78 | -0.824 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -2.51 | -0.986 | -0.78 | -0.824 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.03 | -0.012 | -0.009 | -0.008 |
| Dividends per Share |